Pharmacokinetics of liposomal busulphan in man

Bone Marrow Transplantation
Z HassanM Hassan

Abstract

High doses of busulphan are used in conditioning regimens before stem cell transplantation. Great inter-patient variations in pharmacokinetics and a correlation between toxicity and high systemic exposure of busulphan have been shown in several studies. Some authors have suggested therapeutic drug monitoring and intravenous busulphan aiming to reduce the conditioning-related toxicity. Liposomal busulphan (LBu) might be an alternative to intravenous administration of high-dose busulphan in conditioning. In the present study, we investigated the pharmacokinetics of LBu in man. Seventeen consecutive patients were enrolled in the study. LBu as a single low dose (2 to 8 mg) was given to 12 patients (six adults and six children). Five patients received two high doses of LBu which replaced the first and the last doses of the conditioning regimen. The high dose of LBu was raised from 0.4 to 0.9 mg/kg. A significant linear correlation (r2 = 0.928) was found between the dose of LBu and the area under the plasma concentration-time curve (AUC) (P < 0.001). AUC corrected for 1 mg/kg was 5491 +/- 912 ng.h/ml and 5955 +/- 627 ng.h/ml (low dose of LBu in children and adults, respectively) and 6167 +/- 1385 ng.h/ml and 6933 +/- 656 ng.h/ml (ie ...Continue Reading

References

Jan 1, 1991·Cancer Chemotherapy and Pharmacology·M HassanI Wallin
Jan 1, 1989·Cancer Chemotherapy and Pharmacology·G VassalJ Lemerle
Nov 8, 1980·Lancet·P YellowleesN McIntyre
Oct 14, 1983·Journal of Chromatography·M Hassan, H Ehrsson
Jul 1, 1993·Clinical Pharmacology and Therapeutics·M B RegazziS Quaglini
Jan 1, 1993·Drug and Chemical Toxicology·L A KinneyG L Kennedy
Jan 1, 1996·Cancer Chemotherapy and Pharmacology·H P BhagwatwarB S Andersson
Nov 25, 1998·Bone Marrow Transplantation·Z HassanM Hassan

❮ Previous
Next ❯

Citations

Apr 23, 2002·British Journal of Clinical Pharmacology·Serge CremersJaak Vossen
Jan 1, 2011·Therapeutic Delivery·Joel Richard
Apr 24, 2007·Best Practice & Research. Clinical Haematology·Johan Aschan
Jan 18, 2006·Experimental Hematology·Fredrik SjööMoustapha Hassan
Apr 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stefan O Ciurea, Borje S Andersson
Aug 19, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Seong-Gil RyuKyoo-Hyung Lee
Sep 18, 2009·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Karin KolbeIrene Krämer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.